Sorry, no content matched your criteria.
We don’t often write about initial public offerings (IPOs) here at Private Briefing, but I wanted to make an exception today.
The reason: This soon-to-debut company is a biotech that’s doing late-stage research in an area we just told you about.
The company is Aimmune Therapeutics Inc., a Brisbane, Calif.-based company that will trade on the Nasdaq with the ticker AIMT once it goes public.
The company is developing an oral immunotherapy that’s designed to lessen the effects of peanut allergies, a malady we told you about in a follow-up report on Neogen Corp. (Nasdaq: NEOG) – a stock that’s soared nearly 40% since Radical Technology Profits Editor Michael Robinson told us about the company back in April 2014.
Let’s take a look at the allergen issue – and opportunity – and then “drill down” on Aimmune.